摘要
目的探索青盐方治疗围绝经期综合征的配伍合理性。方法采用网络药理学方法,分别对青盐方中君药(肉苁蓉Cistanchedeserticola)、君+臣药(肉苁蓉+巴戟天Morindaofficinalis)、君+臣+佐药(肉苁蓉+巴戟天+花椒Zanthoxylum bungeanum+牛膝Achyranthesbidentata)、君+臣+佐+使药(肉苁蓉+巴戟天+花椒+牛膝+青盐Halitum)作用于围绝经期综合征的靶点、功能和通路进行预测和筛选,通过数据整合分析解析青盐方防治围绝经期综合征的作用特点及配伍规律。结果74个化合物共作用于围绝经期综合征290个靶点、51个关键靶点,涉及细胞反应、神经-内分泌、免疫等生物过程,主要富集在雌激素受体(estrogen receptor,ER)、磷脂酰肌醇-3-激酶(phosphatidylinositol 3-kinase,PI3K)-蛋白激酶B(protein kinase B,Akt)、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)、缺氧诱导因子1(hypoxia-inducible factor 1,HIF-1)等通路。结论各拆方组通过各靶点相关通路作用于围绝经期综合征的雌激素低下、围绝经期焦虑、生殖道萎缩、骨质疏松病理环节。各配伍组既有不同靶点,也有相同靶点作用于各个症状,协同发挥治疗作用。君药囊括方中216个靶点、40个关键靶点和所有主要通路,依次增加臣、佐、使药后,靶点数量及各通路所涉及的靶点均有不同程度增加,提示君药肉苁蓉在方中的重要地位及其余药味对君药的辅佐补充,解释了其复方配伍合理性。
Objective To explore the compatibility rationality of Qingyan Formula(青盐方)in the treatment of perimenopausal syndrome.Methods Network pharmacology was used to predict and screen the targets,function and pathways related to perimenopausal syndrome in Qingyan Formula including Sovereign(Cistanche deserticola)group,Sovereign-Minister(C.deserticola+Morinda officinalis)group,Sovereign-Minister-Assistant(C.deserticola+M.officinalis+Zanthoxylum bungeanum+Achyranthes bidentata)group and Sovereign-Minister-Assistant-Guide(Jun-Chen-Zuo-Shi)(C.deserticola+M.officinalis+Z.bungeanum+A.bidentate+Halitum)group.The characteristics and compatibility rules of this prescription in preventing and treating perimenopausal syndrome were analyzed combined with data.Results A total of 74 compounds act on 290 targets and 51 key targets of perimenopausal syndrome,mainly involving cell response,neuroendocrine,immune and other related biological processes.Pathway enrichment analysis involved estrogen receptor,PI3 K-Akt,MAPK,HIF-1,and other pathways.Conclusion Each separated compound prescription group acts on the key pathology parts-hypoestrogenia and short-term anxiety,mid-term genital atrophy and long-term osteoporosis of perimenopausal syndrome through various targets and related pathways.Each prescription group not only has different targets,but also has the same targets to act on symptoms,and plays a synergistic therapeutic role.Jun drug group includes 216 related targets,40 key targets and all major pathways in the formula.After Chen,Zuo,and Shi drugs were added in sequence,the number of targets and related pathways were increased to different degree,which indicated the importance of Jun drug-C.deserticola in the formula and the supplement of other drugs to Jun drug,and explains the compatibility rationality.
作者
杨一博
徐颖
王璐
樊媛芳
林娜
YANG Yi-bo;XU Ying;WANG Lu;FAN Yuan-fang;LIN Na(Institute of Chinese Materia Medica,China Academy of Chinese Medical Sciences,Beijing 100700,China)
出处
《中草药》
CAS
CSCD
北大核心
2021年第3期749-757,共9页
Chinese Traditional and Herbal Drugs
基金
国家自然科学基金面上项目(81774203)
国家自然科学基金面上项目(81573632)。
关键词
网络药理学
青盐方
围绝经期综合征
配伍
雌激素低下
围绝经期焦虑
生殖道萎缩症
骨质疏松
network pharmacology
Qingyan Formula
perimenopausal syndrome
compatibility
hypoestrogenia
perimenopausal anxiety
genital atrophy
osteoporosis
